AU762624B2 - Bupropion to treat viral diseases - Google Patents

Bupropion to treat viral diseases Download PDF

Info

Publication number
AU762624B2
AU762624B2 AU17629/00A AU1762900A AU762624B2 AU 762624 B2 AU762624 B2 AU 762624B2 AU 17629/00 A AU17629/00 A AU 17629/00A AU 1762900 A AU1762900 A AU 1762900A AU 762624 B2 AU762624 B2 AU 762624B2
Authority
AU
Australia
Prior art keywords
bupropion
herpes
virus
viral infection
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU17629/00A
Other languages
English (en)
Other versions
AU1762900A (en
Inventor
Christopher William Reindler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PLANISPHERE CORP
Original Assignee
PLANISPHERE CORP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PLANISPHERE CORP filed Critical PLANISPHERE CORP
Publication of AU1762900A publication Critical patent/AU1762900A/en
Application granted granted Critical
Publication of AU762624B2 publication Critical patent/AU762624B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU17629/00A 1998-12-08 1999-12-07 Bupropion to treat viral diseases Ceased AU762624B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13549498P 1998-12-08 1998-12-08
US60/135494 1998-12-08
PCT/AU1999/001089 WO2000033827A1 (en) 1998-12-08 1999-12-07 Bupropion to treat viral diseases

Publications (2)

Publication Number Publication Date
AU1762900A AU1762900A (en) 2000-06-26
AU762624B2 true AU762624B2 (en) 2003-07-03

Family

ID=22468359

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17629/00A Ceased AU762624B2 (en) 1998-12-08 1999-12-07 Bupropion to treat viral diseases

Country Status (14)

Country Link
US (2) US6512011B1 (https=)
EP (1) EP1156791B1 (https=)
JP (1) JP4166955B2 (https=)
AT (1) ATE295159T1 (https=)
AU (1) AU762624B2 (https=)
BR (1) BR9916963A (https=)
CA (1) CA2349487C (https=)
DE (1) DE69925312T2 (https=)
ES (1) ES2242438T3 (https=)
HK (1) HK1042239B (https=)
MX (1) MXPA01005725A (https=)
NZ (1) NZ512716A (https=)
PT (1) PT1156791E (https=)
WO (1) WO2000033827A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030134905A1 (en) * 2002-01-11 2003-07-17 Reindler Christopher William Bupropion to treat viral diseases
DE102004063132A1 (de) * 2004-12-22 2006-07-06 Schmiegel, Wolff, Prof. Dr. Verwendung von Bupropion in Arzneimittel zur Behandlung von Hepatitis C
CN101534808A (zh) * 2005-06-27 2009-09-16 拜维尔实验室国际有限公司 丁氨苯丙酮盐的改良释放配制品
GB2477584A (en) * 2010-02-04 2011-08-10 Biocopea Ltd A compound for use in treating an acute viral infection
WO2011018653A2 (en) * 2009-08-10 2011-02-17 Biocopea Limited Treatment of viral infections
CN108721262A (zh) * 2017-04-13 2018-11-02 中国科学院武汉病毒研究所 安非他酮在制备治疗或预防流感病毒感染的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438138A (en) * 1982-12-06 1984-03-20 Burroughs Wellcome Co. Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
US4507323A (en) * 1984-07-25 1985-03-26 Burroughs Wellcome Co. Treatment of psychosexual dysfunctions
US5753712A (en) * 1994-02-18 1998-05-19 Pinsker; Walter Treatment of migraine headaches and formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438138A (en) * 1982-12-06 1984-03-20 Burroughs Wellcome Co. Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
US4507323A (en) * 1984-07-25 1985-03-26 Burroughs Wellcome Co. Treatment of psychosexual dysfunctions
US5753712A (en) * 1994-02-18 1998-05-19 Pinsker; Walter Treatment of migraine headaches and formulations

Also Published As

Publication number Publication date
DE69925312D1 (de) 2005-06-16
ATE295159T1 (de) 2005-05-15
BR9916963A (pt) 2002-03-05
JP4166955B2 (ja) 2008-10-15
DE69925312T2 (de) 2006-03-09
HK1042239B (en) 2005-12-09
EP1156791A1 (en) 2001-11-28
PT1156791E (pt) 2005-08-31
US6512011B1 (en) 2003-01-28
EP1156791B1 (en) 2005-05-11
US20020173551A1 (en) 2002-11-21
JP2002531495A (ja) 2002-09-24
CA2349487C (en) 2007-09-11
WO2000033827A1 (en) 2000-06-15
CA2349487A1 (en) 2000-06-15
ES2242438T3 (es) 2005-11-01
MXPA01005725A (es) 2003-07-14
EP1156791A4 (en) 2002-05-02
AU1762900A (en) 2000-06-26
HK1042239A1 (en) 2002-08-09
NZ512716A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
US4507323A (en) Treatment of psychosexual dysfunctions
JP4925074B2 (ja) ミルタザピンと１種以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物
US20100323952A1 (en) Nucleoside Analogs in Combination Therapy of Herpes Simplex Infections
AU762624B2 (en) Bupropion to treat viral diseases
EP0171227B1 (en) Use of propiophenone compound
US20030134905A1 (en) Bupropion to treat viral diseases
GB2340037A (en) Compositions comprising bupropion for the treatment of premature ejaculation
US6194460B1 (en) Composition for treating cough induced by angiotensin converting enzyme inhibitors
US4751236A (en) Method for treating genital herpes
CA2244268C (en) Nucleoside analogs in combination therapy of herpes simplex infections
HK1016475B (en) Nucleoside analogs in combination therapy of herpes simplex infections
CA2174240A1 (en) Use of peniclorin for the treatment of posttherapeutic neuralgia
CA2080130A1 (en) Remedy for obstructive pulmonary diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)